PRA Health Sciences (NASDAQ:PRAH) has received a consensus recommendation of “Buy” from the thirteen analysts that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, ten have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $95.18.
Several analysts recently weighed in on PRAH shares. BidaskClub downgraded PRA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 2nd. KeyCorp restated a “buy” rating and issued a $100.00 price target on shares of PRA Health Sciences in a research note on Wednesday, January 31st. Zacks Investment Research upgraded PRA Health Sciences from a “hold” rating to a “buy” rating and set a $102.00 price target on the stock in a research note on Thursday, January 4th. Mizuho downgraded PRA Health Sciences from a “buy” rating to a “neutral” rating and set a $86.00 price target on the stock. in a research note on Wednesday, January 24th. Finally, Credit Suisse Group reaffirmed an “outperform” rating and issued a $104.00 price objective (up from $101.00) on shares of PRA Health Sciences in a research report on Thursday, February 22nd.
Shares of PRAH stock traded up $0.32 during midday trading on Thursday, reaching $88.30. 154,176 shares of the stock were exchanged, compared to its average volume of 422,373. PRA Health Sciences has a 1 year low of $61.93 and a 1 year high of $95.90. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.90 and a current ratio of 0.90. The company has a market capitalization of $5,549.81, a price-to-earnings ratio of 27.61, a price-to-earnings-growth ratio of 1.39 and a beta of 0.49.
PRA Health Sciences (NASDAQ:PRAH) last posted its earnings results on Wednesday, February 21st. The medical research company reported $1.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.02. PRA Health Sciences had a return on equity of 22.77% and a net margin of 3.85%. The firm had revenue of $568.80 million for the quarter, compared to the consensus estimate of $543.78 million. During the same quarter in the prior year, the business earned $0.71 EPS. The business’s revenue for the quarter was up 37.5% on a year-over-year basis. sell-side analysts forecast that PRA Health Sciences will post 3.81 earnings per share for the current year.
A number of hedge funds have recently added to or reduced their stakes in PRAH. New York State Common Retirement Fund lifted its position in PRA Health Sciences by 24.3% in the 3rd quarter. New York State Common Retirement Fund now owns 72,309 shares of the medical research company’s stock valued at $5,508,000 after acquiring an additional 14,129 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of PRA Health Sciences by 26.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 319,233 shares of the medical research company’s stock valued at $24,316,000 after buying an additional 65,887 shares during the period. Legal & General Group Plc lifted its holdings in shares of PRA Health Sciences by 42.7% during the 3rd quarter. Legal & General Group Plc now owns 19,914 shares of the medical research company’s stock valued at $1,514,000 after buying an additional 5,963 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of PRA Health Sciences by 3.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 334,108 shares of the medical research company’s stock valued at $25,449,000 after buying an additional 11,846 shares during the period. Finally, California State Teachers Retirement System lifted its holdings in shares of PRA Health Sciences by 14.0% during the 3rd quarter. California State Teachers Retirement System now owns 78,282 shares of the medical research company’s stock valued at $5,963,000 after buying an additional 9,614 shares during the period. 99.22% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This story was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/17/analysts-set-pra-health-sciences-prah-target-price-at-95-18.html.
About PRA Health Sciences
PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.